Drugs & Therapy Perspectives

, Volume 8, Issue 9, pp 12–16 | Cite as

What scope is there for improving the cost effectiveness of NSAIDs?

Drug Economics and Quality of Life


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bloor K, Maynard A. Is there scope for improving the cost-effective prescribing of nonsteroidal anti-inflammatory drugs? PharmacoEconomics 1996; 9(6): 484–96PubMedCrossRefGoogle Scholar
  2. 2.
    Wynne HA, Campbell M. Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs). PharmacoEconomics 1994; 3(2): 107–23CrossRefGoogle Scholar
  3. 3.
    British National Formulary. No. 31. London: The Pharmaceutical Press. 1996 Mar: 403–12Google Scholar
  4. 4.
    Office of Health Economics. Arthritis. London: Office of Health Economics, 1992Google Scholar
  5. 5.
    Committee on the Safety of Medicines (CSM). Relative safety of oral non-aspirin NSAIDs: current problems in pharmacovigilence. London: CSM/Medicines Control Agency, 1994: 20Google Scholar
  6. 6.
    Maiden N, Madhok R. Misoprostol in patients taking non-steroidal anti-inflammatory drugs: best reserved for elderly patients at high risk. BMJ 1995; 311: 1518–9PubMedCrossRefGoogle Scholar
  7. 7.
    Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomised, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241–9PubMedGoogle Scholar

Copyright information

© Adis International Limited 1996

Personalised recommendations